Hat tip to biosyn’s CEO: 12 years of making the Federal State of Baden-Württemberg Germany’s top pharma hub

Hat tip to biosyn’s CEO: 12 years of making the Federal State of Baden-Württemberg Germany’s top pharma hub

Getting to the top doesn’t mean staying at the top. As chairman of the state chapter of the German Pharmaceutical Industry Association (BPI) for five years after serving as board member for seven, biosyn’s Managing Director, Dr. Thomas Stiefel was pivotal in turning the Federal State of Baden-Württemberg into the booming pharma landscape it is today.

His long leadership of his state’s chapter of the BPI, with its 44 member companies employing a workforce of 6,800, was a challenge Dr. Stiefel is certainly proud of, “We succeeded in increasing the visibility of our industry as one truly important and stable factor of our state economy…of our Pharmaland Baden-Württemberg”. Tucked in Germany’s Southwestern corner and bordering France, Switzerland and Bavaria, the third largest federal state Baden-Württemberg is one of Germany’s economic powerhouses, dubbed “The Land of Inventors”. Dr. Stiefel’s work and biosyn, the medium-sized family-owned business he runs, have done this moniker justice for more than 35 years. In its hat tip, the BPI describes the retiring chairman “as an ever technically expert, competent interlocutor vis-à-vis politics and the media – both valuable and valued.” Joachim A. Thole of the company Dr. Willmar Schwabe GmbH & Co. KG succeeds Dr. Stiefel as chairman of the state association which thanked him for his dedicated service.

  1. state professional politics
  2. small and medium-sized enterprises
  3. pharmaland
  4. corporate information